Our CEO talks to HBW Industry Insight about Maxwellia’s transition into a consumer healthcare company

Praetura leads self-care firm investment round

SPEARHEADING SHIFT TO SELF CARE WITH THREE PHARMACY PRODUCTS IN LAUNCH PIPELINE

Pharmacists at heart of nation's public health

APPOINTMENT OF TIM HOLMES AS HEAD OF SALES

Tim brings over 25 years of UK and global commercial experience

APPOINTMENT OF PARESH BALDANIYA AS HEAD OF QUALITY & REGULATORY AFFAIRS

Paresh has a pharmacy background and a stellar track record

APPOINTMENT OF JACK GRIMSHAW AS FINANCE DIRECTOR

 Jack brings to Maxwellia more than 10 years of finance experience across a range of industries

 TOP MOVER AND SHAKER IN BIOBUSINESS 2019 

Our CEO and founder, Anna Maxwell has been listed in the top 50 movers and shakers of 2019 by BioBusiness 

BIOCITY INVESTS IN MAXWELLIA

Life science incubator and business collective BioCity has announced an investment in Alderley Park-based Maxwellia

POM TO P SWITCHES: WHAT MADE MALOFF PROTECT AND ELLAONE A SUCCESS?

C+D deputy editor Grace Lewis spoke to Anna Maxwell, CEO of Maxwellia, about what makes a successful POM to P change

MAXWELLIA MEETS THE HEALTH SECRETARY

Maxwellia had the opportunity to put the switch agenda on the radar of Matt Hancock, Secretary of State for Health and Social Care

THE POWER OF ALIGNING YOUR BUSINESS TO A GLOBAL GOAL 

Maxwellia is mentioned in Forbes for aligning to Global Goal 3 Good Health 

MAXWELLIA EXPANDS TEAM OF SWITCH EXPERTS AS IT BUILDS THE PRODUCT PIPELINE

Appointments will expedite conversion of prescription medicines to over the counter

UK IS FERTILE GROUND FOR SWITCHING 

With the recent switch of Pfizer’s Viagra, the UK has shown itself to be an open and progressive market for prescription-to-OTC reclassification. 

MAXWELLIA ANNOUNCES FUNDING TO ACCELERATE ITS MISSION FOR SELF CARE

Investment will expedite conversion of prescription medicines to over the counter

BioCity feature Maxwellia CEO on IWD 2021 challenging access to contraception